Afinitor 5mg & 10 mg Tablets
PDF Leaflet Revision Date: 28 October 2022
Clinical Summary
Quick overview from the medicine insert
Indication
Palliative treatment for advanced renal cell carcinoma, breast cancer, neuroendocrine tumors, and renal angiomyolipoma in TSC.
Dosage (summary)
10 mg once daily; may reduce to 5 mg if needed.
Special Populations
- Elderly
- Renal impairment
- Hepatic impairment
Pregnancy & Breastfeeding
Contraindicated in pregnancy; avoid breastfeeding during treatment and for 2 weeks after.
Key Drug Interactions
- Strong CYP3A4 inhibitors
- Moderate CYP3A4 inhibitors
- Strong CYP3A4 inducers
Contraindications
- Hypersensitivity to everolimus
- Concomitant use of live vaccines
Common side effects
- Stomatitis
- Rash
- Fatigue
- Diarrhoea
- Infections
Counselling Points
- Report respiratory symptoms promptly
- Avoid live vaccines
- Use effective contraception during treatment
Serious warnings
- Non-infectious interstitial pneumonitis
- Increased risk of infections
- Hypersensitivity reactions
Important Disclaimer
The Afinitor 5mg & 10 mg Tablets professional information leaflet below is the property of Novartis South Africa and is provided on Medinsert exactly as issued, with no.. alterations or editorial changes. We make every effort to keep content current by updating documents as soon as new versions become available. Medinsert serves as a trusted access point for healthcare professionals, but does not replace official sources or clinical judgement. For more details, please read our full disclaimer. read more>>
Healthcare Professionals Only
This content is for registered healthcare professionals
Sign in or create a free account to read the full package insert.
Free for HPCSA-registered professionals. Powered by Medinsert.
